# Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

> **NCT06323382** · — · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 240 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma
- Anti-PD1/PDL1 Antibody
- Bevacizumab

## Interventions

- **PROCEDURE:** Locoregional therapy
- **DRUG:** Bevacizumab
- **DRUG:** Atezolizumab
- **DRUG:** Tislelizumab
- **DRUG:** Toripalimab
- **DRUG:** Sintilimab
- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT06323382
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-01
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06323382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06323382, "Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06323382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*